SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 - - - - - - - - - - - FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 29, 2002 Date of Report (Date of Earliest Event Reported) GENELABS TECHNOLOGIES, INC. (Exact Name of Registrant as Specified in its Charter) 0-19222 94-3010150 (Commission File Number) (IRS Employer Identification No.) 505 Penobscot Drive Redwood City, California 94063 (Address of Principal Executive Offices) (Zip Code) (650) 369-9500 (Registrant's Telephone Number, including Area Code) Item 5. Other Events On May 29, 2002, Genelabs Technologies, Inc. ("Genelabs") issued a press release regarding its expectation of new action by the U.S Food and Drug Administration on its new drug application for Aslera(TM) (GL701). Item 7. Exhibits EXHIBIT NO. DESCRIPTION 99.1 Press Release dated May 29, 2002. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunder duly authorized. Dated: July 3, 2002 GENELABS TECHNOLOGIES, INC. By: /s/ Heather Criss Keller ------------------------------ Name: Heather Criss Keller Title: Vice President, General Counsel EXHIBIT INDEX EXHIBIT NO. DESCRIPTION 99.1 Press Release dated May 29, 2002.